-
Result of Broker Option / PDMR Dealings
ImmuPharma plc (“ImmuPharma” or “the Company”), announces that it has raised £0.95 million (before expenses) pursuant to a Broker Option following the announcement made on 3 August 2022. Under the terms of a placing agreement entered into by the Company with Stanford Capital Partners Limited (“SCP”) and SPARK Advisory Partners Limited on 3 August, the…
-
INVESTOR PRESENTATION Via Investor Meet Company Platform | 12 midday (BST) | 4 August 2022
ImmuPharma is pleased to announce that Tim McCarthy, CEO and Tim Franklin, COO, will provide a live investor presentation via the Investor Meet Company platform today, 4 August 2022 at 12:00pm BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until…
-
Subscription and Placing to raise £1.1 million; Sharing Agreement; to progress product portfolio. Broker Option to raise up to £1.3m
Related Party Transactions ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce a subscription and a placing to raise c£1.1 million (the “Subscription” and “Placing”) through the issue of 21,818,182 new ordinary shares of 1 pence each in the Company (“Ordinary Shares”) at a price of 5 pence…
-
Initiation of research
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, notes that its joint broker, Stanford Capital Partners (“SCP”) has today initiated research coverage on the Company. The full text of the report can be accessed via SCP’s website: www.stanfordcp.co.uk/research/ and via Research Tree. Investors are required to self-certify and register in order to access…
-
2022 Result of ANNUAL GENERAL MEETING – all resolutions passed
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed, details of which are contained in the table below. ImmuPharma’s Chairman & CEO, Tim McCarthy said: “We are delighted to have had such overwhelming support from right across…
-
Avion seeks final regulatory guidance as it prepares for the start of the international Phase 3 trial of Lupuzor™ in Lupus patients
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce that, having met all the Food and Drug Administration’s (“FDA”) requirements, Avion Pharmaceuticals (“Avion”), its US partner, has confirmed that it has sought final regulatory guidance from the FDA, as it actively prepares for the start of the international Phase 3…
-
FDA confirms response date for Type C Meeting as 29th August 2022
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce that its US partner for Lupuzor™ (P140), Avion Pharmaceuticals (“Avion”), has advised that it has now received Type C Meeting confirmation from the Food and Drug Administration (“FDA”). The statement of purpose, objectives, and proposed agenda of the Type C meeting…
-
Notice of AGM & Annual Report & Accounts
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, confirms that the Notice of Annual General Meeting (“AGM”) has been posted to shareholders. The Annual Report and Accounts for the year ended 31 December 2021 will be posted to shareholders on 6 June 2022. These documents will be available shortly, in electronic…
-
FINAL RESULTS ANNOUNCEMENT for the year ended 31 December 2021
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2021 (the “Period”). Key Highlights (including post Period review) Loss for the Period of £8.2m (£6.9m at 31 December 2020) Research and development expenses of £3.7m (31 December 2020: £2.4m)…
